Mitral stenosis medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Sudarshan Srivats, M.D., M.P.H.[2]; Mohammed A. Sbeih, M.D.[3]; Cafer Zorkun, M.D., Ph.D. [4]; Rim Halaby, M.D. [5]
|
Mitral Stenosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mitral stenosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Mitral stenosis medical therapy |
|
Risk calculators and risk factors for Mitral stenosis medical therapy |
Overview
Medical therapy for mitral stenosis (MS) is directed at anticoagulation for thromboembolism prevention, heart rate control to prolong diastolic filling and lower the transmitral gradient, diuretics for congestion, and secondary prophylaxis of rheumatic fever. Medical therapy relieves symptoms and reduces complications but does not alter the mechanical obstruction or disease progression; definitive relief of severe symptomatic MS with favorable valve morphology requires percutaneous mitral balloon commissurotomy (PMBC) or surgery.
Anticoagulation
Thromboembolism is a major source of morbidity in MS, with systemic embolization in 10%–20% of patients. Risk is driven primarily by atrial fibrillation (AF) and left atrial (LA) stasis rather than stenosis severity per se, and thrombi frequently form outside the LA appendage, a mechanism distinct from non-valvular AF.[1][2]
VKA, Not DOACs, for Rheumatic MS
A vitamin K antagonist (VKA), not a direct oral anticoagulant (DOAC), is the standard of care for rheumatic MS with AF. The INVICTUS trial randomized 4,531 patients with rheumatic heart disease–associated AF to rivaroxaban 20 mg daily versus dose-adjusted VKA. VKA was superior: the primary composite outcome (stroke, systemic embolism, MI, or vascular/unknown death) favored VKA (restricted mean survival 1,675 vs. 1,599 days), with fewer ischemic strokes (65 vs. 90) and lower mortality with VKA, driven by reduced sudden cardiac death and pump failure, and no significant difference in major bleeding.[3] The 2023 ACC/AHA/ACCP/HRS AF guidelines recommend warfarin over DOACs in patients with rheumatic MS or moderate-to-severe MS and AF, independent of CHA₂DS₂-VASc score (Class I, LOE B-R).[4] The 2026 ACC Scientific Statement on DOACs reaffirms that DOACs should not be used in moderate-to-severe rheumatic MS with AF.[5]
Target INR is 2.0–3.0, with time in therapeutic range optimized (goal ≥70%).[4]
Recommendations for Anticoagulation in Rheumatic MS (2020 ACC/AHA)
| Class I |
| 1. In patients with rheumatic MS and 1) AF (paroxysmal, persistent, or permanent), 2) a prior embolic event, or 3) an LA thrombus, anticoagulation with a VKA is indicated. (Level of Evidence: C-LD) |
The following considerations are retained from the 2008 ACC/AHA guideline where not superseded:
- Class IIb (LOE B): Anticoagulation may be considered for asymptomatic patients with severe MS and LA dimension ≥55 mm.[1]
- Class IIb (LOE C): Anticoagulation may be considered for patients with severe MS, an enlarged LA, and spontaneous echo contrast.[1]
Heart Rate Control
Tachycardia shortens diastolic filling time, raising the transmitral gradient and LA pressure disproportionately, and is poorly tolerated in MS.[6]
Recommendations for Heart Rate Control in Rheumatic MS (2020 ACC/AHA)
| Class IIa |
| 1. In patients with rheumatic MS and AF with a rapid ventricular response, heart rate control can be beneficial. (Level of Evidence: C-LD)
|
Agents
- Beta blockers (e.g., metoprolol, atenolol): reduce heart rate and prolong diastolic filling. Benefit is greatest in younger patients with higher resting heart rates; older patients with chronotropic incompetence may not benefit and may worsen with beta-blockade.[6]
- Ivabradine: selectively lowers heart rate via I(f) channel inhibition without negative inotropic or vasodilatory effects. Multiple small RCTs show efficacy at least comparable to beta-blockers for heart rate reduction and exercise duration in sinus rhythm; a meta-analysis of 5 RCTs (356 patients) found lower maximum heart rate versus beta-blockers (mean difference −5.03 bpm). Particularly useful when beta-blockers are contraindicated (e.g., reactive airway disease). Brand-name Corlanor was discontinued in the US in January 2026; generic ivabradine remains available.[7][8][9]
- Non-dihydropyridine calcium channel blockers (diltiazem, verapamil): alternative rate-control agents, particularly for AF; use cautiously with significant LV dysfunction.
- Digoxin: useful for rate control in AF, often combined with a beta-blocker or calcium channel blocker; targeted to clear indications (AF rate control, symptomatic RV or LV dysfunction).
The benefit of heart rate control in sinus rhythm is population-dependent: younger patients with higher resting heart rates benefit most, whereas older patients with chronotropic incompetence may not benefit and may worsen with beta-blockade.[6]
Diuretics and Congestion Management
Diuretics reduce preload and relieve pulmonary congestion in symptomatic MS but do not alter natural history.[10]
- Loop diuretics (furosemide, bumetanide, torsemide) are the mainstay for acute pulmonary edema and chronic congestion.
- Aldosterone antagonists (spironolactone, eplerenone) and thiazide-type agents may be added for refractory congestion.
- Overdiuresis must be avoided: excessive preload reduction compromises cardiac output through the fixed stenotic orifice.[6]
- Sodium restriction is a reasonable adjunctive measure.
Management of Acute Atrial Fibrillation
New-onset AF can precipitate acute hemodynamic deterioration from loss of atrial contraction and rapid ventricular response.
- Immediate management: anticoagulation and rate control with negative dromotropic agents (beta-blockers, non-dihydropyridine calcium channel blockers, digoxin).
- Cardioversion if rate control is inadequate and hemodynamic compromise persists.
- Rate vs. rhythm control: depends on AF duration, hemodynamic response, LA size, prior episodes, and embolic history. Rhythm control is harder to sustain in rheumatic MS because the rheumatic process itself causes progressive atrial fibrosis and enlargement.
Secondary Prevention of Rheumatic Fever
Long-term antistreptococcal prophylaxis is indicated for all patients with rheumatic heart disease, including after valve surgery or replacement.[6]
| Class I |
| In patients with rheumatic heart disease, secondary prevention of rheumatic fever is indicated. (Level of Evidence: C-EO) |
Antibiotic Regimens
| Antibiotic | Dosage |
|---|---|
| Penicillin G benzathine (preferred) | 1.2 million units IM every 4 weeks (every 3 weeks in high-risk situations) |
| Penicillin V potassium | 250 mg orally twice daily |
| Sulfadiazine | 1 g orally once daily (≤27 kg: 0.5 g once daily) |
| Macrolide/azalide (penicillin + sulfadiazine allergy) | Varies |
Adapted from the 2020 ACC/AHA guideline and Gerber et al. 2009.[6][11] The pain of benzathine penicillin G injection can be reduced when reconstituted with 1% lidocaine; adherence remains a major global challenge.[10]
Duration of Prophylaxis
| Category | Duration |
|---|---|
| Rheumatic fever with carditis and persistent valvular heart disease | 10 years or until age 40 (whichever is longer); lifelong if high GAS exposure risk |
| Rheumatic fever with carditis but no residual valvular disease | 10 years or until age 21 (whichever is longer) |
| Rheumatic fever without carditis | 5 years or until age 21 (whichever is longer) |
Secondary prophylaxis is required even after valve replacement.[6]
Infective Endocarditis Prophylaxis
Endocarditis prophylaxis is not indicated for native-valve MS. Prophylaxis is reserved for patients with prosthetic valves, prior endocarditis, certain congenital heart diseases, or cardiac transplant recipients with valvulopathy.[6]
Pregnancy Considerations
MS is among the highest-risk valvular lesions in pregnancy; even mild MS may be poorly tolerated because physiologic tachycardia and increased cardiac output raise transvalvular gradients.[12]
- Pre-conception: asymptomatic women with severe rheumatic MS (MVA ≤1.5 cm²) considering pregnancy should be evaluated for PMBC before conception (Class IIa, LOE C-LD).[6]
- During pregnancy: beta-1–selective beta-blockers (e.g., metoprolol) are first-line for heart rate control, with diuretics as needed for congestion. Vigorous volume depletion must be avoided to protect uteroplacental perfusion.[12]
- Anticoagulation: VKA is indicated for AF, LA thrombus, prior embolism, severe MS, spontaneous echo contrast, LA volume index ≥60 mL/m², or heart failure, with careful discussion of fetal risks and heparin bridging strategies.[12]
- Refractory symptoms: PMBC may be performed during pregnancy (preferably in the second trimester) with abdominal shielding by an experienced operator if medical management fails. Congenital MS is generally not amenable to balloon valvuloplasty.[12][6]
Perioperative Management
The 2024 AHA/ACC perioperative guidelines address MS in noncardiac surgery (NCS):[13]
- Class I (LOE B-NR): Patients with severe MS should be evaluated for the need for MV intervention before elective NCS.
- Class IIa (LOE C-EO): In patients with severe MS who cannot undergo MV intervention before NCS, perioperative invasive hemodynamic monitoring is reasonable.
- Class IIb (LOE C-LD): In patients with severe MS who cannot undergo MV intervention before NCS, perioperative heart rate control (beta-blockers, CCBs, ivabradine, digoxin) may be considered to prolong diastolic filling time.
Perioperative goals include a low-normal heart rate, high-normal systemic vascular resistance, adequate preload, and maintenance of sinus rhythm; tachycardia, hypoxia, and hypercapnia should be avoided.[13]
2014_2017 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary (DO NOT EDIT)[14]
Medical Therapy (DO NOT EDIT)
| Class I |
"1. Anticoagulation (vitamin K antagonist or heparin) is indicated in patients with:
|
| Class IIa |
| "1. Heart rate control can be beneficial in patients with MS and AF and fast ventricular response. (Level of Evidence: C) " |
| Class IIb |
| "1. Heart rate control may be considered for patients with MS in normal sinus rhythm and symptoms associated with exercise. (Level of Evidence: B) " |
Basic Principles of Medical Therapy (DO NOT EDIT)
| Class I |
| "1. Secondary prevention of rheumatic fever is indicated in patients with rheumatic heart disease, specifically mitral stenosis (MS). (Level of Evidence: C) " |
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease (DO NOT EDIT)[1]
| Class I |
| "1. Anticoagulation is indicated in patients with mitral stenosis and atrial fibrillation (paroxysmal, persistent, or permanent). (Level of Evidence: B) " |
| "2. Anticoagulation is indicated in patients with mitral stenosis and a prior embolic event, even in sinus rhythm. (Level of Evidence: B) " |
| "3. Anticoagulation is indicated in patients with mitral stenosis with left atrial thrombus. (Level of Evidence: B) " |
| Class IIb |
| "1. Anticoagulation may be considered for asymptomatic patients with severe mitral stenosis and left atrial dimension greater than or equal to 55 mm by echocardiography. (Level of Evidence: C) " |
| "2. Anticoagulation may be considered for patients with severe mitral stenosis, an enlarged left atrium, and spontaneous contrast on echocardiography. (Level of Evidence: C) " |
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Bonow RO, Carabello BA, Chatterjee K; et al. (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172.
- ↑ Kim JY, Kim SH, Myong JP, Kim YR, Kim TS, Kim JH; et al. (2019). "Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis". J Am Coll Cardiol. 73 (10): 1123–1131. doi:10.1016/j.jacc.2018.12.047. PMID 30871703.
- ↑ Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A; et al. (2022). "Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation". N Engl J Med. 387 (11): 978–988. doi:10.1056/NEJMoa2209051. PMID 36036525 Check
|pmid=value (help). - ↑ 4.0 4.1 Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM; et al. (2024). "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation". J Am Coll Cardiol. 83 (1): 109–279. doi:10.1016/j.jacc.2023.08.017. PMID 38033089 Check
|pmid=value (help). - ↑ Kumbhani DJ, Armbruster AL, Cheng RK; et al. (2026). "Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement". J Am Coll Cardiol. doi:10.1016/j.jacc.2026.05.033.
- ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F; et al. (2021). "2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 143 (5): e72–e227. doi:10.1161/CIR.0000000000000923. PMID 33332150 Check
|pmid=value (help). - ↑ Agrawal V, Kumar N, Lohiya B, Sihag BK, Kumar S (2016). "Metoprolol vs Ivabradine in patients with mitral stenosis in sinus rhythm". Int J Cardiol. 221: 562–6. doi:10.1016/j.ijcard.2016.07.022. PMID 27424019.
- ↑ Saggu DK, Narain VS, Dwivedi SK, Sethi R, Chandra S, Puri A; et al. (2015). "Effect of Ivabradine on Heart Rate and Duration of Exercise in Patients With Mild-to-Moderate Mitral Stenosis: A Randomized Comparison With Metoprolol". J Cardiovasc Pharmacol. 65 (6): 552–4. doi:10.1097/FJC.0000000000000222. PMID 25469805.
- ↑ Ghadimi N, Kaveh S, Shabaninejad H, Lijassi A, Ghaffari Darab M, Namdar P; et al. (2019). "Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis". Int J Clin Pharm. 41 (1): 22–29. doi:10.1007/s11096-018-00778-z. PMID 30478496.
- ↑ 10.0 10.1 Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E; et al. (2020). "Contemporary Diagnosis and Management of Rheumatic Heart Disease: Implications for Closing the Gap: A Scientific Statement From the American Heart Association". Circulation. 142 (20): e337–e357. doi:10.1161/CIR.0000000000000921. PMID 33170076 Check
|pmid=value (help). - ↑ Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST; et al. (2009). "Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association". Circulation. 119 (11): 1541–51. doi:10.1161/CIRCULATIONAHA.109.191959. PMID 19246689.
- ↑ 12.0 12.1 12.2 12.3 Lindley KJ, Bairey Merz CN, Asgar AW, Bello NA, Chandra S, Elmariah S; et al. (2021). "Management of Women With Congenital or Inherited Cardiovascular Disease From Pre-Conception Through Pregnancy And Postpartum: JACC Focus Seminar 2/5". J Am Coll Cardiol. 77 (14): 1778–1798. doi:10.1016/j.jacc.2021.02.026. PMID 33832599 Check
|pmid=value (help). - ↑ 13.0 13.1 Thompson A, Fleischmann KE, Smilowitz NR, de Las Fuentes L, Mukherjee D, Aggarwal NR; et al. (2024). "2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery". J Am Coll Cardiol. 84 (19): 1869–1969. doi:10.1016/j.jacc.2024.06.013. PMID 39320315 Check
|pmid=value (help). - ↑ Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000029. PMID 24589852.
- ↑ Nishimura, Rick A.; Otto, Catherine M.; Bonow, Robert O.; Carabello, Blase A.; Erwin, John P.; Fleisher, Lee A.; Jneid, Hani; Mack, Michael J.; McLeod, Christopher J.; O’Gara, Patrick T.; Rigolin, Vera H.; Sundt, Thoralf M.; Thompson, Annemarie (2017). "2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Circulation. 135 (25). doi:10.1161/CIR.0000000000000503. ISSN 0009-7322.